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Overview

Electrochemical Techniques for Subsecond
Neurotransmitter Detection in Live Rodents
Kevin N Hascup and Erin R Hascup*
Alterations in neurotransmission have been implicated in numerous neurodegenerative and neuropsychiatric disorders, including Alzheimer disease, Parkinson disease, epilepsy, and schizophrenia. Unfortunately, few techniques support the measurement
of real-time changes in neurotransmitter levels over multiple days, as is essential for ethologic and pharmacodynamic testing.
Microdialysis is commonly used for these research paradigms, but its poor temporal and spatial resolution make this technique
inadequate for measuring the rapid dynamics (milliseconds to seconds) of fast signaling neurotransmitters, such as glutamate and
acetylcholine. Enzymatic microelectrode arrays (biosensors) coupled with electrochemical recording techniques have demonstrated
fast temporal resolution (less than 1 s), excellent spatial resolution (micron-scale), low detection limits (≤200 nM), and minimal
damage (50 to 100 µm) to surrounding brain tissue. Here we discuss the benefits, methods, and animal welfare considerations of
using platinum microelectrodes on a ceramic substrate for enzyme-based electrochemical recording techniques for real-time in
vivo neurotransmitter recordings in both anesthetized and awake, freely moving rodents.
Abbreviations: DOPAC, 3,4-dihydroxyphenylacetic acid; FAST, fast analytical sensing technology; GABA, γ-aminobutyric acid;
MEA, microelectrode array.

Alterations in neurotransmission have been implicated in numerous CNS disorders including Alzheimer disease, Parkinson
disease, Huntington disease, amyotrophic lateral sclerosis, depression, anxiety, addiction, epilepsy and schizophrenia. 13 As
the number of transgenic animal models designed to mimic human pathophysiology of CNS disorders exponentially increases,
it has become paramount to quantify changes in neurotransmitter levels during the progression from healthy to diseased
phenotype. Unfortunately, few techniques support the measurement of real-time changes in neurotransmitter levels over
multiple days, as is essential for ethological or pharmacotherapy studies. Microdialysis typically is used for these research
paradigms, but its poor temporal and spatial resolution, makes
this technique inadequate for measuring the rapid dynamics
(milliseconds to seconds) of fast signaling neurotransmitters,
such as glutamate and acetylcholine.37,63,66 As such, advances
in enzymatic biosensors coupled with electrochemical recording techniques have closed the gap in our understanding of
neurotransmission.16,19,24,25,27,30,32,35,36,41,47,49,67 Here we discuss the
benefits, methods, and animal welfare considerations of using
platinum microelectrodes on a ceramic substrate for enzymebased electrochemical recording techniques for real-time in vivo
neurotransmitter recordings in both anesthetized and awake,
freely moving rodents.
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Microdialysis Compared with Electrochemical
Biosensors

Since the early 1980s, microdialysis has been used routinely
to sample neurotransmitters and neuromodulators in the extracellular space of the CNS. This technique uses a semipermeable membrane that acts as a capillary to control the diffusion
of extracellular neurotransmitters along their concentration gradients,17,37,65 which subsequently are measured using offline techniques such as HPLC coupled with electrochemical detection.
Because microdialysis is a sample collection system, the entire
interstitial fluid around the probe is obtained to enable offline
determination of multiple analytes at femtomolar concentrations.
Typically, microdialysis samples are collected every 5 to 20 min,
although advances in the detection methods coupled with online HPLC have allowed for subminute sampling rates.38,40,57,64
However, these approaches are complicated, labor-intensive, and
expensive and therefore are impractical for routine use by many
laboratories.
Although minute sampling rates may be sufficient to study
most catecholaminergic neurotransmissions, the temporal resolution of microdialysis is too slow to detect the millisecond release
and uptake of many excitatory or inhibitory neurotransmitters.
This is the first of several limitations of microdialysis. Second is
the low spatial resolution of the dialysis probes. A typical dialysis
probe has a diameter of 150 to 400 µm with an average length of
1 to 4 mm— significantly larger than the synaptic cleft—thereby
precluding analyte sampling close to the synapse. The large size
of the dialysis probe coupled with the rapid uptake of glutamate
into astroglial transporters hampers accurate measurement of
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glutamate release, clearance, and resting levels by microdialysis.18,25,63 Third, the constant perfusion of artificial cerebral spinal
fluid into the CNS is speculated to dilute neurotransmitter levels.25 Fourth, implantation of the microdialysis probe results in
short- and long-term cellular damage, as evidenced by the histologic, physiologic, biochemical, and neurochemical changes in
CNS tissue that can occur within a 2.8-mm circumference around
the implant site5,12,23 and result in aberrant neurotransmitter release and uptake as far as 220 µm from the probe.4,68
As such, electrochemical techniques have been developed to
address the limitations of microdialysis. In vivo electrochemistry
is a simple yet powerful means for real-time, online monitoring
of neurotransmitter overflow in the extracellular space.1,42 A potentiostat controls an applied potential at the working microelectrode (typically an inert material such as platinum, iridium, or
carbon) compared with a Ag/AgCl reference. With a sufficient
potential, molecules are either oxidized or reduced, depending
upon their intrinsic electrochemical properties, directly at the
working electrode surface. The currents generated from Faradaic
reactions are linear with regard to the concentration of the electroactive molecule(s) in the tissue surrounding the microelectrode.
For a more detailed explanation of the electrochemistry involved,
we refer the reader to the literature.1,21,26,28,31,42,45
These microelectrodes initially were single-carbon fiber wires
used for the detection of dopamine, serotonin, and norepinephrine;
however, they have had limited success for monitoring nonelectroactive neurotransmitters, such as γ-aminobutyric acid (GABA),
glutamate, and acetylcholine. A new generation of microelectrodes
therefore was developed. By using photolithographic techniques,
researchers have been able to reproducibly pattern multiple recording sites onto a single biocompatible substrate, thereby creating a
microelectrode array (MEA). This development has become extremely important, considering that MEA measure analytes only
from small foci (microns) of tissue directly surrounding the recording surface. In addition, electrodes with multiple recordings sites
can be arranged geometrically to measure analyte concentrations
from 2 or more distinct brain regions28 (Figure 1 A through C). MEA
designed by using photolithographic techniques have reproducible
high spatial (microns) resolution and minimal damage to tissue (50
to 100 µm).23 When coupled with constant-potential amperometry,
the measurement of current at a constant, fixed potential, neurochemical events can be monitored as rapidly as every millisecond
or less21,45 over multiple days29,59 with the ability to simultaneously
detect single-unit activity and local field potentials.23,69,70
In conjunction with constant-potential amperometry, MEA are
not without their pitfalls. They have poor chemical resolution,
such that it is difficult to distinguish between multiple electroactive
molecules that are present in vivo. To further complicate matters,
several interfering compounds (ascorbic acid, 3,4-dihydroxyphenylacetic acid [DOPAC], 5-hydroxyindoleacetic acid, and uric acid)
exist and can be measured at oxidation potentials similar to those of
biogenic amines. Fortunately, these limitations can be addressed by
using MEA surface modifications (exclusion layers and enzymes)
as well as self-referencing techniques that allow for selective monitoring of specific neurochemicals, including dopamine, glutamate,
choline, acetylcholine, glucose, lactate, and adenosine.

MEA Surface Modifications

Prior to in vivo studies, MEA are subjected to numerous cleaning and coating procedures to ensure successful detection of
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specific neurotransmitters. These procedures have been thoroughly detailed elsewhere.28,31 Few neurochemicals are electrochemically active at potentials of ≤ +0.7 V on platinum surfaces
compared with a Ag/AgCl reference electrode, and those that
are detectable are often not the molecule of interest. Furthermore,
compounds such as ascorbic acid, DOPAC, 5-hydroxyindolacetic
acid, and uric acid are present in the extracellular fluid in 100- to
1000-fold higher concentrations than are biogenic amines and
amino-acid transmitters.1,42,43 To discriminate against these molecules and improve the selectivity for the analyte of interest,
various protective films can be applied onto the MEA surface.
Nafion is an anionic Teflon derivative whose negatively charged
sulfonic acid groups repel anionic interferents (such as ascorbic
acid, DOPAC, 5-hydroxyindolacetic acid, and uric acid) and concentrate cationic analytes (such as dopamine, serotonin, and norepinephrine) at the platinum recording surfaces. The preparation
of Nafion on the MEA makes this film a reliable choice of measuring neurotransmitters over multiple days (7 to 10 d) in awake,
freely moving rats and mice.29,59 However, because Nafion slightly
concentrates biogenic amines to the recording surface,1 m-phenylenediamine can be used in CNS regions with high tissue levels of monoamines. m-Phenylenediamine is electropolymerized
onto the MEA, and the selectivity is likely achieved by forming a
size exclusion layer that prevents larger molecules (ascorbic acid,
dopamine, and DOPAC) from reaching the recording surface,
whereas smaller molecules (nitric oxide and hydrogen peroxide,
H2O2) are able to pass through the matrix.20,41 Finally, when measuring analytes that exist in millimolar concentrations (glucose
and lactate), an additional polyurethane layer is applied. Polyurethane improves the linearity of the MEA for high concentrations
of glucose or lactate yet provides an additional exclusion layer
that prevents the diffusion of biogenic amines, thereby making
the MEA nearly interferent free.9
Enzymes provide a means to convert a molecule that is not
inherently electroactive (and thus not measurable with this technique) into a reporter molecule (such as H2O2) that is oxidized
at the platinum recording surfaces. The current measured from
the oxidation of H2O2 generated during the enzymatic breakdown is directly proportional to the analyte concentration.28,31
Table 1 provides a list of available enzymes and their potential
uses. Some compounds require multiple enzymes to convert
them to a reporter molecule, such as acetylcholine, adenosine,
and GABA. A chemical crosslinking procedure is used to immobilize the enzymes to the MEA recording surface, thereby
stabilizing the enzymes and prolonging their activity. Researchers have used several of these enzymes, including L-glutamate
oxidase,3,6-8,11,14,15,19,24,25,27,29,34,39,46-48,50,55,56,59-62 acetylcholinesterase,10,22,44
choline oxidase,8,50-54 L-lactate oxidase9 and L-glucose oxidase6 for
in vivo neurochemical measurements. Although uncoated MEAs
have a long shelf life, we recommend using a coated MEA within
2 wks.

Self-Referencing

The development of MEA with multiple, uniform recording
surfaces that are patterned in a precise geometrical configuration allows researchers to apply similar films or enzymes on 2
separate, yet spatially adjacent, recording surfaces. This coating
procedure allows for recognition of possible interfering agents
and their removal from the analyte signal. Essentially, a self-referencing MEA can be considered the electrochemical equivalent
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Figure 1. MEA designs and enzyme coating. Photographs of the fully fabricated (A) anesthetized and (B) freely moving MEA. (C) Magnified images of
tips with several electrode recording sites patterned in unique geometrical configurations. The name of each tip is shown in the upper right, whereas
the size of the recording sites is shown at the lower left. Where applicable, the distance between groups of recording sites is labeled. (D) Self-referencing
schematic of an MEA coated with an exclusion and an enzyme layers for measurement of glutamate. Site 1 is an active recording site with the glutamate
oxidase –BSA–glutaraldehyde coat in blue, and site 2 is a sentinel site with the BSA–glutaraldehyde coat in pink for the R2 MEA. Yellow indicates the
exclusion layer, either Nafion or m-phenylenediamine.

of performing double-beam spectroscopy. Ideally, the only difference between the 2 sites is that one responds to the analyte of interest whereas the other does not. This difference is accomplished
by coating an enzyme specific to an analyte of interest on one
recording site and applying a chemically inactive protein to the
other recording site (Figure 1 D). This chemically inactive site is
often referred to as the control or sentinel site. The enzyme-coated
site detects the analyte of interest in addition to everything else
that the control site detects. Applying an inactive protein layer to
the control site is necessary to minimize differences between the
diffusional properties of molecules reaching the different recording surfaces.6,8 Without this coating, the control sites may respond
faster to interferents than do the analyte-detecting sites. Ensuring
similar response times of the recording surface is imperative to
remove the background and interfering signals from the analyte
signal during offline subtraction. Using these offline subtraction

methods, we are able to eliminate unknown artifacts from the
analyte signal and enhance the signal-to-noise ratio. This procedure is often referred to as ‘self-referencing,’ and demonstrations
of these principles are provided elsewhere.6,8,11
In addition to the ability to remove interferents that contribute
to an analyte signal, self-referencing recordings can remove periodic or random noise and account for sensor drift, which may
occur over prolonged implantation time. This ability provides
an obvious advantage because smaller changes in current (lower
detection limits) can be achieved in vivo.6 In addition, self-referencing is useful during real-time (subsecond) monitoring of
analytes in the brain. If the analyte-detecting site responds in the
absence of a response on the control sites, the signal is considered
to be due to analyte. For this situation, the control site is not used
to quantify the analyte but rather to determine whether an interfering signal is present.6
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Table 1. Enzymes
Substrate
Acetylcholinesterase

Product

Acetylcholine

Choline, acetic acid

Alcohol oxidase

Alcohol, O2

H2O2, aldehyde

Ascorbate oxidase

Ascorbate, O2

Dehydroascorbate

Aspartate oxidase

Aspartate, O2

H2O2, NH4+, oxaloacetate

Catalase

H2O2

O2

Cholesterol oxidase

Cholesterol, O2

H2O2, 4-cholesten-3-one

Choline oxidase

Choline, O2

H2O2, betaine

Galactose oxidase

D-galactose, O2

H2O2, d-galacto-hexodialose

Glucose oxidase

Glucose, O2

H2O2, gluconic acid

L-glutamate oxidase

L-glutamate, O2

H2O2, α-ketoglutarate

GABase

GABA, α-ketoglutarate

Succinic semialdehyde, l-glutamate, NADPH, H+

Glutaminase

Glutamine

NH4+, l-glutamate

Glycerol kinase

Glycerol, ATP

Glycerol-3-phosphate, ADP

Glycerol-3-phosphate oxidase

Glycerol-3-phosphate, O2

H2O2, dihydroxyacetone phosphate

Hexokinase

ATP, glucose

Glucose-6-phosphate, ADP

Horseradish peroxidase

H2O2

H2O, O2

Lactate oxidase

Lactate, O2

H2O2, pyruvate

Lysine oxidase

Lysine, O2

H2O2, NH4+, 6-amino-2-oxohexanoic acid

Pyruvate oxidase

Pyruvate, O2, phosphate

H2O2, CO2, acetyl phosphate

Sarcosine oxidase

Sarcosine, O2

H2O2, glycine, formaldehyde

Xanthine oxidase

Xanthine, O2

H2O2, uric acid

MEA Calibration

Microfabricated MEA generally have highly reproducible recording surfaces; however, manufacturing procedures may cause
slight variations to each recording surface that could alter their
responses to analytes. In addition, current-exclusion and enzymecoating procedures can result in different layer thicknesses; therefore, each MEA must be calibrated in vitro prior to experimentation
to determine standard curves. Essentially, the calibration is used to
equate a change in current from the oxidation of H2O2 to a proportional change in analyte concentration from the oxidase enzyme
generating H2O2 at physiologic temperature (37 °C) and pH (7.4).
The current, in picoamperes, is measured by a potentiostat, such
as the Fast Analytical Sensing Technology (FAST) 16mkIII system
(Quanteon, Nicholasville, KY), and generates a standard curve
for each recording site. In addition, known interferents such as
ascorbic acid, are added during the calibration to test the selectivity of the recording sites to the analyte of interest compared
with interferents. Finally, compounds used for pharmacodynamic
studies should be tested in vitro to ensure they are not inherently
electrochemically active, a situation that would falsely contribute
to neurotransmitter levels during recordings. Once calibration is
complete, the standard curve is used to determine the concentration of the measured analyte from the change in current during in
vivo experimentation.

MEA Implantation and
Neurotransmitter Recording

These MEA were designed for routine recordings of neurotransmission in the CNS of anesthetized or awake, freely moving
rats and mice. The following section outlines the procedure for
the preparation and surgical implantation of the MEA for in vivo
CNS recordings. All protocols should be approved by the IACUC
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prior to proceeding. The procedures we outline here are based on
methods used by the authors at several different institutions in
the United States, Europe, and Canada. All procedures were approved with their respective IACUC.
Nonsurvival surgical procedure for recordings in anesthetized
rodents Recording in anesthetized animals are ideal for performing dose–response studies in multiple CNS regions of a single
animal. MEA can be reused multiple times for these experiments,
helping to reduce costs. However investigators must remember
that anesthetics can directly affect receptors. For example, ketamine, a noncompetitive n-methyl-d-aspartate receptor antagonist, would not be an ideal anesthetic for glutamatergic studies.2,58
Rodents are anesthetized with urethane (1.25 g/kg IP) or another IACUC-approved anesthetic, such as isoflurane. When the
animal no longer responds to sensory stimuli, it is placed in a stereotaxic frame (Kopf Instruments, Tujunga, CA) and monitored
for responsiveness throughout the experiment approximately
every 10 to 15 min. A Deltaphase Isothermal Pad (Braintree Scientific, Braintree, MA) is placed between the metal frame and
the animal to maintain its body temperature at 37 °C. In the case
of mice, these heating pads are bulky, so a water pad connected
to a heated water bath (Stryker, Kalamazoo, MI) can be used to
maintain body temperature. All surgical tools must be sterilized
prior to surgery, typically by autoclave. The fur over the skull
is shaved, wiped with a povidone–iodine solution, and a heatsterilized scalpel is used to make a small incision along the midline of the scalp. The skin is reflected by using bulldog clamps
(Fine Science Tools, Foster City, CA). Once the skull is exposed,
a rotary tool (Dremel, Mount Prospect, IL) with bit size 107 (rats)
or 105 (mice) is used to perform a craniotomy large enough to
lower the MEA (Quanteon) into the CNS region of interest. With
heat-sterilized forceps, the overlying dura is pulled laterally to
expose the surface of the brain. Finally, a small hole is drilled in
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a remote location from the recording site for an Ag/AgCl reference electrode (A-M Systems, Sequim, WA). The coated tip of the
Ag/AgCl reference electrode (disinfected in 70% ethanol prior
to coating) is inserted into the brain and held in place by using
dental acrylic (Lang Dental MFG, Wheeling, IL). The MEA is attached to the stereotaxic arm via an electrode manipulator (Kopf
Instruments), and a micromanipulator (Narishige International,
East Meadow, NY) can be used to precisely raise or lower the
MEA in the CNS.
Throughout the experiment, the animal should be evaluated
for anesthetic depth and physiologic functions, and appropriate
actions should be taken to prevent animal discomfort. Depending on the length of the surgery or experiment—typically 1 to 6
h depending on the anesthesia used and experimental design—
fluid replacement with a subcutaneous injection of Ringers solution might be necessary. Once the experiment has concluded,
the animal should be euthanized according to approved IACUC
protocols.
Survival surgical procedure for recordings in awake, freely
moving rodents Survival surgeries for long-term (multiple days)
neurotransmitter recordings typically use chronically implanted
MEA23-25,29,30,59 and are necessary for ethologic testing to correlate
phenotypic and neurotransmitter alterations during behavior-related tasks. Some behavioral paradigms, such as the Morris water
maze, are ill-suited for these types of recordings. In our experience, MEA have successfully been implanted in rodents without
noticeable changes in normal behavior (eating, grooming), with
minimal damage to the surrounding tissue,23 and without infection or irritation at the implant site for as long as 12 mo. However,
in vivo MEA viability varies depending on the characteristic being tested. For example, glutamate has been reliably measured
for at least 14 d after implantation.23 Positive responses to local
application of H2O2 (tests MEA viability but not enzyme-coating
function) have been observed for at least 90 d after implantation.59
Finally, electrophsyiologic studies have used MEA to record local
field potentials for as long as 180 d after implantation.23 The data
indicate that the enzyme coating on the MEA deteriorates long
before the MEA stops functioning.
During the week prior to surgery, rodents are acclimated to
the recording chamber for 1 h each on 5 separate days to help
prevent stress or anxiety due to introduction to novel stimuli during recordings. On the day of surgery, the MEA is calibrated and
prepared for chronic implantation. All surgical instruments are
autoclaved prior to initial use and heat-sterilized in a glass-bead
sterilizer during surgery, and the operative work site is disinfected with 70% ethanol. All surgeries are performed in a Vertical
Laminar Flow Workstation with HEPA filtration (Microzone, Ottawa, Canada). Rats or mice are anesthetized with approximately
2% isoflurane and placed in a stereotaxic apparatus fitted with a
gas anesthesia head holder and mask and nonrupture ear bars
(Kopf Instruments). Animal body temperature is maintained at 37
°C by using a Deltaphase isothermal heating pad (BrainTree Scientific), and the animals’ eyes are lubricated with artificial tears
(The Butler Company, Columbus, OH) to help maintain moisture
and prevent infection. Prior to incision, the fur directly over the
skull is shaved, and the skin directly on top of the animal’s head
is wiped with povidone–iodine solution to clean the incision area
and to reduce the likelihood of infection. A scalpel is used to make
a single incision along the midline, and the skin is reflected using bulldog clamps (Fine Science Tools). Then 3 small holes are

drilled in the skull in the quadrants adjacent to the MEA implantation site, for placement of stainless steel skull screws. A fourth
hole is drilled contralateral from the recording site for insertion
of the Ag/AgCl reference electrode wire. Next, 3 small stainless
steel screws (Small Parts, Logansport, IN; disinfected in 70% ethanol) are threaded into the skull to serve as anchors, and care is
taken so that the screw tips do not touch brain tissue or dura. A
small (maximum, 2 mm × 2 mm) craniotomy is performed over
the recording area, and a calibrated MEA pedestal assembly is
implanted based on stereotactic coordinates. The assembly is secured with approximately 4 layers of dental acrylic (Lang Dental
MFG), with care taken to cover as much of the pedestal assembly
as possible. The dental acrylic should have a smooth texture, and
excess acrylic should be removed from the skin surface to avoid
postsurgical irritation, which may cause the animal to scratch its
head frequently and potentially damage the implant. Depending
on the length of the surgery, fluid replacement with a subcutaneous injection of Ringers solution might be necessary.
Once the dental acrylic has dried, the rodent is removed from
anesthesia, and oral acetaminophen (mice: 120 mg/kg PO every 4 h; rats: 100 mg/kg PO every 4 h)33 is given to help alleviate
postoperative pain. The described survival surgeries typically
last approximately 30 to 45 min. Because of this short duration,
analgesics can be given immediately preoperatively or postoperatively. Because acetaminophen is given orally, rodent access to
postoperative analgesics can be maintained if necessary, in accordance with approved dosing schedule for the analgesic. However,
subsequent doses of acetaminophen or other analgesics rarely are
necessary with this procedure, as the rodents usually do not show
signs of pain or distress (lack of eating, drinking, or grooming;
hunched posture) after initial administration of acetaminophen.
Animals are returned to their home cages and placed on a heating pad until fully recovered from anesthesia. Food and water
are provided ad libitum. During this recovery phase, trained personnel should monitor continuously for signs of distress, and
appropriate measures should be taken to alleviate such symptoms. Once fully recovered from anesthesia and in the absence of
signs of distress, animals are returned to their housing facility and
allowed 72 h to recover prior to initiation of behavioral testing.
Although infection or inflammation is possible near the implantation site, we have had great success with the procedures outlined
and have had no apparent incidence of infection or inflammation
in chronically implanted rodents. At any time after surgery, animals developing signs of pain or distress that cannot be alleviated
should be euthanized according to approved IACUC protocols.
Rodents are typically group housed before surgery, but are
single-housed after surgery. This is done to avoid interactions
with other animals that may interfere with healing of the skin
surrounding the implant site. After surgery, rodents are housed
in traditional solid-bottom rodent cages with bedding, and no
changes in housing are necessary, including those involving the
feeder and wire-bar lid. Additional bedding or enrichment can be
added if deemed necessary for the experiment or for animal well
being, but is not necessary for recovery.

Conclusion

Electrochemistry is a powerful technique for studying online,
real-time neurotransmission in anesthetized and awake freely
moving rats and mice. This technique has helped researchers elucidate altered neurochemical signaling in numerous models of
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CNS disorders, leading to improved translational therapeutic
outcomes. Good surgical technique and animal care are essential
to the collection of valid data using this approach.
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